Associated Papers
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.
Virtanen T et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2026
Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer.
Jani CT et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer.
Hosseini N et al.
Cancer Research, 2025
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.
Tsukahara S et al.
Cancer Medicine, 2025
Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
Shah K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Zengin ZB et al.
Prostate Cancer and Prostatic Diseases, 2025
Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer.
Nørgaard M et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.
Bae TH et al.
Cancer Research, 2025
Histopathologic and Molecular Characterization of IDH-Mutant Prostatic Adenocarcinoma.
Samueli B et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
The androgen receptor amino-terminal domain: structure, function and therapeutic potential.
Hunter I et al.
Endocrine Oncology (bristol, England), 2025
Comparison of androgen receptor mutation detection between plasma extracellular vesicle DNA and cell-free DNA and its relationship to prostate cancer prognosis.
Ding T et al.
Annals of Medicine, 2024
Structural perspectives on the androgen receptor, the elusive shape-shifter.
Johnson MJ et al.
Steroids, 2024
TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
Yoshida S et al.
Molecular Oncology, 2024
Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.
Beatson EL et al.
International Journal of Molecular Sciences, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Anselmino N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Mechanistic insights into steroid hormone-mediated regulation of the androgen receptor gene.
Gillen AD et al.
Plos One, 2024
Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer.
Bratic Hench I et al.
Cancers, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.
Zivanovic A et al.
Nar Cancer, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM et al.
Nature Communications, 2023
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Dorff T et al.
Research Square, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
Snaterse G et al.
Prostate Cancer and Prostatic Diseases, 2023
Symphony in the crowd: Key genetic alterations in prostate cancer.
Masud N
Cancer Innovation, 2023
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
Reed-Perino DE et al.
Journal for Immunotherapy of Cancer, 2023
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK et al.
Acta Crystallographica. Section F, Structural Biology Communications, 2023
α-Mangostin Promotes In Vitro and In Vivo Degradation of Androgen Receptor and AR-V7 Splice Variant in Prostate Cancer Cells.
Nauman MC et al.
Cancers, 2023
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance.
Alegre-Martí A et al.
Science Advances, 2023
A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Béraud C et al.
Frontiers in Oncology, 2023
Simulating androgen receptor selection in designer yeast.
Zhang H et al.
Synthetic and Systems Biotechnology, 2022
Yeast-based evolutionary modeling of androgen receptor mutations and natural selection.
Zhang H et al.
Plos Genetics, 2022
Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M et al.
Endocrine-related Cancer, 2022
Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A et al.
International Journal of Biological Macromolecules, 2022
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.
Radaeva M et al.
Cells, 2022
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
Kwan EM et al.
The Prostate, 2022